About Altheos
Altheos was a Healthcare company based in San Francisco (United States) founded in 2010. It focuses on RD and manufacturing of drugs for various therapeutic areas. It operates on a B2B model. Altheos has raised $32.5 million across 2 funding rounds from investors including Canaan, Bay City Capital and Novo Holdings. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Research and Development and Drug Manufacturing. Its competitors include Nephron Pharmaceuticals, AmbioPharm and Aiolos Bio; 3 of its 3 listed competitors have raised funding.
Company details
Altheos, established in 2010 and currently in Dissolved stage, focuses on providing healthcare solutions, producing pharmaceutical products, research and development, and drug manufacturing. Focuses on RD and manufacturing of drugs for various therapeutic areas. Adapting to market demands with innovation and client-focused strategies.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Website altheos.com
- Total Equity Funding$32.5M (USD)
in 2 rounds
- Latest Funding Round$12.5M (USD), Series A
Feb 2012
- InvestorsCanaan
& 4 more
Funding Insights of Altheos
Altheos has successfully raised a total of $32.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.5 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.5M
- Total Rounds 2
- Last Round Series A — $12.5M
- First Round $20M
(Apr 2010)
- Investors Count 5
All 2 funding rounds of Altheos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2012 | $12.5M | Series A | – | – | |
| Apr 2010 | $20M | Series A | – | Bay City Capital |
5 investors in total: 5 institutional.
Investors in Altheos
Altheos has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Canaan, Bay City Capital and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Life sciences startups are funded by a non-profit angel network. | lifescienceangels.com | Sunnyvale, United States | ||
A healthcare-focused venture capital fund based in Santa Clara. | atheneosventures.com | Santa Clara, USA |
Investor details for Altheos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Altheos
3 dated milestones of Altheos across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Altheos is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series A, of $12.5M.
Competitors of Altheos
Altheos has 3 listed competitors in our database, 3 of them funded. They include Nephron Pharmaceuticals, AmbioPharm and Aiolos Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nephronpharm.com | 1937 | Florida, Puerto Rico | $625M | 1,578 | Sterile pharmaceutical products are manufactured and contract services are provided. | |
| ambiopharm.com | 2006 | North Augusta, United States | $24M | 186 | CDMO and analytical services for peptide development are provided. | |
| aiolosbio.com | 2023 | Boston, United States | $245M | Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions |
Detailed competitors of Altheos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Altheos (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Altheos
Altheos was founded in 2010.
Altheos is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Altheos is a funded company, having raised a total of $32.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Apr 2010.
Altheos, established in 2010 and currently in Dissolved stage, focuses on providing healthcare solutions, producing pharmaceutical products, research and development, and drug manufacturing. Focuses on RD and manufacturing of drugs for various therapeutic areas. Adapting to market demands with innovation and client-focused strategies.
Altheos's top competitors include Nephron Pharmaceuticals, Aiolos Bio and AmbioPharm.
Altheos has 5 investors. Key investors include Canaan, Bay City Capital, Novo Holdings, Life Science Angels, and Atheneos Ventures.